Contraceptive Postmarketing Studies To Be Discussed By FDA Advisory Committee
This article was originally published in The Pink Sheet Daily
Executive Summary
Agency seeks advice on how to get better information on safety and efficacy of hormonal contraceptives.
You may also be interested in...
User Fees Would Fund Safety Oversight Throughout Product Life Cycles
PDUFA proposal expands scope of funding after FDA concludes that safety problems can occur well after a drug’s launch.
Patient-Reported Outcomes Data Can Be Used In Labeling, FDA Draft Guidance Says
Document outlines the evaluation and development of appropriate PRO instruments to collect outcomes data that supports labeling claims.
Rx Misbranding Penalties Should Be Stronger To Stop Counterfeiting, FDA Says
Industry also seems supportive of the idea, while Pew touts the power of the power of track-and-trace as a deterrent.